Browse studies

Find your next paid study

11 recruiting studies matching your filters

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis

This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NAS…

Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver Fibrosis

Estimated

~$10 – $7,500

Boehringer IngelheimNCT06632444

Phase 2

A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)

The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (S…

Liver FibrosisHepatic Cirrhosis

Estimated

~$10 – $7,500

AstraZenecaNCT07610837

Observational

Randomized Feasibility Trial of Isocaloric Navy-Bean Substitution in Adults With MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

This study is a 24-week randomized crossover feasibility trial evaluating an isocaloric navy-bean dietary substitution in 40 adults with metabolic dysfunction-…

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Liver FibrosisMetabolic Dysfunction-Associated Steatohepatitis (MASH)

Estimated

~$10 – $6,250

Icahn School of Medicine at Mount SinaiNCT07730853

Phase 4

A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health con…

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis (MASH)+2 more

Estimated

~$10 – $6,250

The Cleveland ClinicNCT06374875

Observational

Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modific…

ObesityLiver DiseasesLiver Fibrosis+16 more

Estimated

~$10 – $7,500

Pichamol Jirapinyo, MD, MPHNCT06138821

Phase 2

Phase II Clinical Trial of Low-dose Erlotinib for Hepatocellular Carcinoma Chemoprevention

This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellul…

Cirrhosis, LiverAdvanced Liver Fibrosis

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT04172779

Clinical Correlation Evaluation of the LIVERFAStTM Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against MR-based Liver Assessment, Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and …

Liver Fibrosis Due to NASHMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseAlcohol Liver Disease

Estimated

~$10 – $1,050

Fibronostics USA, IncNCT06797596

Phase 2

Low Dose Thyroid Hormone, Mitochondrial Fatty Acid Oxidation, and Treatment of Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem. It…

Nonalcoholic SteatohepatitisLiver Fibrosis

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT05526144

Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance…

Metabolic Associated Fatty Liver DiseaseMetabolic Associated Steatotic Liver DiseaseCirrhosis, Liver+5 more

Estimated

~$10 – $675

Foundation for the National Institutes of HealthNCT07122700

Phase 1

A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults With Child Pugh A and B Cirrhosis

This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifi…

Cirrhosis, LiverLiver FibrosisAscites Hepatic

Estimated

~$10 – $8,750

PharmaINNCT05490888

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

Magnetic resonance elastography is a novel non-invasive MRI technique to obtain stiffness of soft tissues such as liver, heart, kidneys, etc. In this imaging t…

Heart FailureLiver FibrosisCardiac Transplant Rejection+1 more

Estimated

~$10 – $1,125

Arunark KolipakaNCT01757730